Skip to Content

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

The first results from the ProBio study show that treatment with ARPI leads to longer PFS, but Henrik Grönberg predicts that there will be many larger publications and results from the study in the future.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top